cancer t-cell therapy
what the score rests on
Each fact is ranked among earlier disclosures that have the same fact. A percentile of 86 means 86% of comparable earlier records had fewer. The four measures below have weights learnt from what happened to those earlier records.
- Claims2886th percentileUSPTO
- Earlier patents it cites7096th percentileUSPTO
- Independent claims117th percentileUSPTO
- Earlier patents by the inventors4995th percentileUSPTO
- NIH funding$6.6 million66th percentileNIH RePORTER
- Separate grants498th percentileNIH RePORTER
- Different patent owners in the field795th percentileUSPTO
dealbreaker checks
- ClearOwnershipThe university is the owner of record, with a clean assignment chain.
- ClearLegal challengesNo challenge filed at the patent office.
- ClearPatent lifeAbout 20 years of patent life left at the disclosure date.
- Not checkedBlocking patentsClaims not yet compared with patents in force.
what happened later
Shown for context and never used in the score, because it is dated after the disclosure. The patent was licensed to Novartis, and the therapy became the first CAR T-cell treatment approved by the FDA, in August 2017.